 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || DCSZ11 / DynamiCure Biotech
Trial completion date, Trial primary completion date, Monotherapy, Metastases: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Nov 22, 2024
P1, N=257, Recruiting, Sponsor: DynamiCure Biotechnology
Trial completion date: May 2025 --> Dec 2026 | Trial primary completion date: Apr 2025 --> Dec 2025
- DCBY02 / DynamiCure Biotech
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Monotherapy, Metastases: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 5, 2024
P1, N=5, Terminated, Sponsor: DynamiCure Biotechnology
Trial completion date: May 2025 --> Dec 2026 | Trial primary completion date: Apr 2025 --> Dec 2025 N=108 --> 5 | Trial completion date: Oct 2024 --> Feb 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2024 --> Feb 2024; Review of Data, and our other compound is a better option
- || DCBY02 / DynamiCure Biotech
Enrollment closed, Monotherapy, Metastases: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Dec 22, 2023
P1, N=108, Active, not recruiting, Sponsor: DynamiCure Biotechnology
N=108 --> 5 | Trial completion date: Oct 2024 --> Feb 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2024 --> Feb 2024; Review of Data, and our other compound is a better option Recruiting --> Active, not recruiting
- || DCSZ11 / DynamiCure Biotech
Enrollment change, Monotherapy, Metastases: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Nov 8, 2023
P1, N=251, Recruiting, Sponsor: DynamiCure Biotechnology
Recruiting --> Active, not recruiting N=96 --> 251
- ||| DCSZ11 / DynamiCure Biotech
Enrollment open, Monotherapy, Metastases: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jul 3, 2023
P1, N=96, Recruiting, Sponsor: DynamiCure Biotechnology
N=96 --> 251 Not yet recruiting --> Recruiting
- ||| DCSZ11 / DynamiCure Biotech
New P1 trial, Monotherapy, Metastases: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 27, 2023
P1, N=96, Not yet recruiting, Sponsor: DynamiCure Biotechnology
- || DCBY02 / DynamiCure Biotech
Enrollment change, Monotherapy, Metastases: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 16, 2023
P1, N=96, Recruiting, Sponsor: DynamiCure Biotechnology
Not yet recruiting --> Recruiting N=192 --> 96
- || DCBY02 / DynamiCure Biotech
Enrollment change, Monotherapy, Metastases: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Dec 27, 2022
P1, N=192, Recruiting, Sponsor: DynamiCure Biotechnology
N=192 --> 96 N=96 --> 192
- ||| DCBY02 / DynamiCure Biotech
Enrollment open, Monotherapy, Metastases: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 22, 2022
P1, N=96, Recruiting, Sponsor: DynamiCure Biotechnology
N=96 --> 192 Not yet recruiting --> Recruiting
- | DCBY02 / DynamiCure Biotech
New P1 trial, Monotherapy, Metastases: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Aug 11, 2022
P1, N=96, Not yet recruiting, Sponsor: DynamiCure Biotechnology